GSDMB showed predominantly protective effects: increased expression in multiple T‐cell subsets associated with lower risk of UC, Crohn disease, rheumatoid arthritis, and ankylosing spondylitis, but showed an opposite liability in primary sclerosing cholangitis. Here, GSDMB is linked to ankylosing spondylitis.